Verrica Pharmaceuticals (NASDAQ:VRCA) Earns Hold Rating from Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Verrica Pharmaceuticals (NASDAQ:VRCA) in a research report sent to investors on Tuesday morning, Benzinga reports.

Several other equities research analysts also recently issued reports on the company. Royal Bank of Canada downgraded Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $11.00 to $2.00 in a report on Tuesday. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd. Finally, TD Cowen lowered their price objective on Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, October 21st. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.60.

Verrica Pharmaceuticals Trading Down 44.2 %

NASDAQ:VRCA opened at $0.80 on Tuesday. Verrica Pharmaceuticals has a 52 week low of $0.75 and a 52 week high of $11.41. The company has a debt-to-equity ratio of 29.58, a quick ratio of 2.23 and a current ratio of 2.36. The stock’s fifty day moving average is $1.67 and its two-hundred day moving average is $5.17.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.12). The firm had revenue of ($1.78) million during the quarter, compared to analysts’ expectations of $7.53 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 3,102.90%. On average, equities research analysts predict that Verrica Pharmaceuticals will post -1.5 EPS for the current year.

Institutional Trading of Verrica Pharmaceuticals

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Verrica Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock valued at $7,511,000 after acquiring an additional 7,609 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Verrica Pharmaceuticals by 8.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company’s stock valued at $428,000 after acquiring an additional 4,393 shares during the last quarter. Key Financial Inc purchased a new stake in Verrica Pharmaceuticals during the 2nd quarter valued at approximately $69,000. Rhumbline Advisers raised its stake in Verrica Pharmaceuticals by 20.4% during the 2nd quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock valued at $194,000 after acquiring an additional 4,514 shares during the last quarter. Finally, Quest Partners LLC purchased a new stake in Verrica Pharmaceuticals during the 2nd quarter valued at approximately $50,000. 42.45% of the stock is owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.